UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039249
Receipt number R000044751
Scientific Title A study on the effects of application of compounded stenone cream (fermented product enriched with plant stenones) on subcutaneous fat and visceral fat.
Date of disclosure of the study information 2020/01/24
Last modified on 2020/06/10 14:38:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the effects of application of compounded stenone cream (fermented product enriched with plant stenones) on subcutaneous fat and visceral fat.

Acronym

A study on the effects of application of compounded stenone cream (fermented product enriched with plant stenones) on subcutaneous fat and visceral fat.

Scientific Title

A study on the effects of application of compounded stenone cream (fermented product enriched with plant stenones) on subcutaneous fat and visceral fat.

Scientific Title:Acronym

A study on the effects of application of compounded stenone cream (fermented product enriched with plant stenones) on subcutaneous fat and visceral fat.

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim is to examine the effects of application of compounded stenone cream (test product) on subcutaneous fat and visceral fat in slightly obese women aged 35-64 years.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Subcutaneous fat area

Key secondary outcomes

Visceral fat area, Total fat area, Weight, Body fat percentage, Adiponectin, and Leptin


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Apply 5g of compounded stenone cream (test product) at a time once daily after leaving the bath. Continue it for 8 weeks.

Interventions/Control_2

Apply 5g of placebo at a time once daily after leaving the bath. Continue it for 8 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <=

Age-upper limit

65 years-old >

Gender

Female

Key inclusion criteria

1. 35 to 64 years old.
2. Women.
3. BMI 25.0 kg/m2 or greater.

Key exclusion criteria

1. Those are currently receiving some types of drug treatment (e.g. treatment affecting obesity, hyperlipidemia, and lipid metabolism).
2. Those who are receiving nutrition therapy or physical therapy under a doctor's supervision.
3. Those who cannot stop taking health foods or supplements (those which may affect obesity, hyperlipidemia, and lipid metabolism) during the study period.
4. Those who cannot stop drinking alcohol the day before a test.
5. Those who have a current or a past medical history of severe diseases.
6. Those who have skin diseases (e.g. atopic dermatitis) or a hypersensitivity.
7. Those who have a current or a past medical history of drug or food allergy.
8. Those who have a current or a past medical history of drug or alcohol dependence.
9. Those who have metals implanted in the body due to surgery etc.
10. Those who have a cardiac pacemaker or an implantable medical device placed in the body.
11. Those who have claustrophobia.
12. Those who work night shifts.
13. Smokers.
14. Those who are currently pregnant or breastfeeding or those who want to become pregnant during the study period.
15. Those who are currently participating in another clinical trial or those who took a test product and completed another clinical trial in a month.
16. Those who were determined by the principal investigator or a sub-investigator to be an unsuitable subject for this study.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Tadashi
Middle name
Last name Nagashima

Organization

DAISAN KASEI CO.,LTD.

Division name

Fermentation

Zip code

290-0045

Address

50-5,Goi Minamikaigan,Ichihara-shi,Chiba

TEL

0436-22-3155

Email

t-nagashima@dsk-goi.com


Public contact

Name of contact person

1st name Naomi
Middle name
Last name Yuzawa

Organization

imeQ RD inc.

Division name

Sales department

Zip code

169-0051

Address

2-14-6, Nishi-Waseda, Shinjyuku, Tokyo

TEL

03-6205-6222

Homepage URL


Email

n-yuzawa@imeqrd.co.jp


Sponsor or person

Institute

imeQ RD inc.

Institute

Department

Personal name



Funding Source

Organization

DAISAN KASEI CO.,LTD.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Suda Clinic institutional review board

Address

2-8-14,Takadanobaba,Shinjyuku,Tokyo

Tel

03-6205-6222

Email

suda-clinic_irb@imeq.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 01 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 12 Month 13 Day

Date of IRB

2019 Year 12 Month 25 Day

Anticipated trial start date

2020 Year 03 Month 01 Day

Last follow-up date

2020 Year 04 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 01 Month 24 Day

Last modified on

2020 Year 06 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044751


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name